Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
3.0
Journals
Diagnostics
Special Issues
New Progress in Diagnosis and Management of Asthma
share announcement

New Progress in Diagnosis and Management of Asthma

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 961

Special Issue Editor

Prof. Dr. Kęstutis Malakauskas

E-Mail Website
Guest Editor
Department of Pulmonology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania
Interests: asthma; eosinophil; airway remodeling; lung function testing; biomarkers; biologics

Special Issue Information

Dear Colleagues,

Asthma is the most common non-communicable disease worldwide, and the morbidity rate increases every year. As a heterogeneous disease, asthma is often underdiagnosed or -treated. The disease complexity explains its inclusion in the list of incurable diseases, so only phenotypic diagnosis and individualized treatments can control the course and severity of the disease and improve the patients’ quality of life.

This Special Issue aims to address the latest findings in the field of diagnostics and management of asthma. The original works may include novel molecular and epigenetic biomarkers, asthma phenotyping, as well as the latest advances in management of severe asthma through the precision medicine, selectively targeting the eosinophils, neutrophils, T2 and non-T2 cytokines, and alarmins.

In this Special Issue, original research articles and reviews are welcome.

The topics include, but are not limited to:

  • Pathophysiology in asthma;
  • Genomics, metabolomics, and epigenetics in asthma;
  • Biomarkers in asthma;
  • Airway remodeling in asthma;
  • Phenotypes and endotypes in asthma;
  • Advances in therapy in asthma;
  • Biologics in asthma.

I look forward to receiving your contributions.

Prof. Dr. Kęstutis Malakauskas
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • biomarkers
  • phenotyping
  • management
  • biological
 

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1163 KiB  
Article
Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma
by Jolita Palacionyte, Andrius Januskevicius, Egle Vasyle, Airidas Rimkunas, Skaidrius Miliauskas and Kestutis Malakauskas
Diagnostics 2024, 14(13), 1345; https://doi.org/10.3390/diagnostics14131345 - 25 Jun 2024
Viewed by 750
Abstract
Anti-interleukin (IL) 5 is an effective treatment modality for inhibiting eosinophilic inflammation in patients with T2-high severe asthma. The aim of this study was to determine the clinical efficacy and serum levels of type 2 inflammatory mediators during 24 weeks of mepolizumab treatment [...] Read more.
Anti-interleukin (IL) 5 is an effective treatment modality for inhibiting eosinophilic inflammation in patients with T2-high severe asthma. The aim of this study was to determine the clinical efficacy and serum levels of type 2 inflammatory mediators during 24 weeks of mepolizumab treatment in patients with T2-high severe asthma. Eighteen patients with T2-high severe asthma were enrolled in this study. All patients received 100 mg of mepolizumab subcutaneously every 4 weeks and were retested at 4, 12, and 24 weeks. A clinical examination, asthma control test (ACT), and spirometry were performed; fractional exhaled nitric oxide (FeNO) levels were evaluated; and blood samples were drawn at every visit. Type 2 inflammation mediator levels were measured using enzyme-linked immunosorbent assay (ELISA). The blood eosinophil level significantly decreased, the ACT score and FEV1 increased after 4 weeks of mepolizumab treatment with the same tendency after 12 and 24 weeks (p < 0.05), and the FeNO level did not change (p > 0.05). A total of 27.8% of patients reached clinical remission criteria after 24 weeks of mepolizumab treatment. IL-33 and eotaxin significantly increased (p < 0.05) while IL-5, IL-13, thymic stromal lymphopoietin (TSLP), soluble IL-5 receptor subunit alpha (sIL-5Rα), and soluble high-affinity immunoglobulin E receptor (sFcεRI) decreased, with the same tendency after 12 and 24 weeks (p < 0.05). The serum levels of immunoglobulin (Ig) E and IL-4 and IL-25 levels did not change during mepolizumab treatment compared to baseline (p > 0.05). In conclusion, treatment with mepolizumab over 24 weeks improved lung function and asthma control in T2-high severe asthma patients, with nearly one-third achieving clinical remission criteria, and affected the balance of type 2 inflammatory mediators. Full article
(This article belongs to the Special Issue New Progress in Diagnosis and Management of Asthma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop